IGF-1 LR3 In A Nutshell

IGF-1 LR3 is a peptide that isn’t to be confused with IGF-1 because it is comprised of arginine instead of glutamic acid. Complete with 83 essential amino acids, IGF-1 LR3 has been thought to be an important solution we can leverage for muscle growth and repair, as well as the improvement and reparation of skeletal tissues.
There are a few presumed benefits of IGF-1 LR3 that are sprouting up as a result of studies performed using IGF-LR3 but there can never be enough research. If you’re interested in performing your own research, we suggest you acquire a small portion of IGF-1 LR3 before breaking the bank. At Guru Peptides, you can get IGF-1 LR3 in the form of bottled white powder, measuring up to 1mg.

What Is IGF-1 LR3?

IGF-1 LR3 is a synthetic protein so it’s not going to be found naturally occurring in humans, animals, or even plants for that matter. Created in laboratories around the world, IGF-1 LR3 is comprised of naturally occurring substances but that doesn’t make it any less synthetic. Essentially a modified version of IGF-1, or human insulin-like growth factor 1, IGF-1 LR3 is upwards of 300% more potent and effective than the IGF-1 sub base. Remaining active for around two times as long, IGF-1 LR3 is ideal for research and development purposes.

IGF-1 LR3 Findings – A Timeline

We know that all IGF plays important roles in the development of tissue and many studies have focused on the association between IGF and muscle growth. As of late, there has been a push for development of an anti-degenerative disease solutions using IGF. Modifying the naturally produced IGF is presumed to be our best bet for degenerative disease treatment or even prevention.
Over the past couple of decades, we’ve had the technology needed to harvest essential ingredients needed to create such solutions. Starting near the turn of the century, research projects have improved at an impressive rate:
1999 – Dr. Tirapegui was able to prove rats introduced to IGF-1 saw impressive gains in muscle mass, skeletal density, and cartilage growth. Other similar studies were conducted around this time, laying the groundwork for the upcoming years.
2001 – After the turn of the century, people started to speculate about the potential improvements humans could see when it comes to IGF-1 LR3 and athletics. No doubt the professional competition circuits and leagues have started to notice what’s going on about this time.
2003 – For the next few years, more studies were conducted on mice and rats using IGF-1 LR3. The purpose of these studies varied but almost all of them revolved around the idea that IGF-1 LR3 could be used as a supplement for physical therapy in individuals suffering from muscle degenerative disease or people struggling after serious surgery.
2008 – We started to perfect doses and proper application levels in mice and rats. For the next 3 or so years, scientists perfected their solutions with their eyes on human testing next.
2012 – As development neared human testing, an alarming trend was starting to manifest: cancer rates in the test animals started to skyrocket.
2017 – While cancer rates are still much higher than preferred, the benefits of IGF-1 LR3 introduction can no longer be denied. Big pharma has started to focus efforts on producing a drug that will improve quality of life for people struggling with muscle or skeletal degeneration in spite of the potential cancer concerns.

IGF Cancer Risk

The downside to developing medication that prevents muscle degeneration is the unintended side effect; IGF-1 creates an environment where cancer can grow and thrive. Obviously problematic. Until we develop a solution that ignores cancer cell production, it’s not going to be a viable fix for people suffering from muscle degeneration. One thing’s for certain… Whoever is the first to develop a solution that doesn’t increase cancer rates will ensure their family will never have to work again.

1. Tirapegui, J. “Effect of Insulin-like Growth Factor-1 (IGF-1) on Muscle and Bone Growth in Experimental Models.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, July 1999, www.ncbi.nlm.nih.gov/pubmed/10719568.
2. Adams, Gregory R. “Insulin-like Growth Factor in Muscle Growth and Its Potential Abuse by Athletes.”US National Library of Medicine, Western Journal of Medicine, July 2001, www.ncbi.nlm.nih.gov/pmc/articles/PMC1071449/.

For Scientific Research Use Only

Despite the fact that scientific research study has actually been performed on animal test subjects to in order to identify Igf-1 lr3’s scope of operational mechanics and performance including its theoretical advantages and possibly negative adverse effects, it ought to be noted that any findings that have actually been linked to the peptide are still based in present laboratory research study. Since Igf-1 lr3 is currently in this research phase, any matters of purchase connecting to this peptide must solely be included to scientific research study, and any study regarding the peptide should just be consisted of to the restrictions of a strictly regulated environment such as a laboratory or medical research center.